Vineet Laboratories Limited

VINEETLAB

INE505Y01010

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:13:56 28/06/2024 pm IST			5-day change	1st Jan Change
58.59 ^INR	-0.29%		-6.33%	-28.24%

30/05	Vineet Laboratories CEO Resigns	MT
29/05	Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director	CI

Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director

May 29, 2024 at 07:33 pm IST

The Board of Directors of Vineet Laboratories Limited in its meeting held on May 29, 2024 has approved the resignation of Mr. Satish Pandurang Samant from the office of Executive Director effective from May 29, 2024.

Latest news about Vineet Laboratories Limited

Vineet Laboratories CEO Resigns	30/05	MT
Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director	29/05	CI
Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Chief Executive Officer	29/05	CI
Vineet Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	29/05	CI
Vineet Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Vineet Laboratories Limited Announces Appointment of Mr. Rameshkumar Bandari as Company Secretary and Compliance Officer	10/11	CI
Vineet Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023	10/11	CI
Vineet Laboratories Limited Announces Resignation of Nirosha Ravikanti as Company Secretary / Compliance Officer of the Company	28/23/28	CI
Vineet Laboratories Names CEO	16/23/16	MT
Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as Chief Executive Officer	16/23/16	CI
Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as an Additional Executive Director	16/23/16	CI
Vineet Laboratories Limited Appoints Ranga Raju Alluri as Non-Executive Director	30/23/30	CI
Vineet Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	12/23/12	CI
Vineet Laboratories Limited Announces Board Changes	12/23/12	CI
Vineet Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/23/29	CI
Vineet Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/23/29	CI
Vineet Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI

Chart Vineet Laboratories Limited

Duration

Period

More charts

Company Profile

Vineet Laboratories Limited is engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. It also exports API intermediates, fine chemicals, and custom synthesis molecules.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VINEET LABORATORIES LIMITED	-28.24%	64.8L
ELI LILLY AND COMPANY	+55.32%	82TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	31TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
ROCHE HOLDING AG	+2.04%	22TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr
PFIZER, INC.	-2.81%	16TCr